

Comisión Honoraria para la  
Lucha Antituberculosa y  
Enfermedades Prevalentes




CAMPAÑA DE  
VACUNACIÓN  
COVID-19

# SITUACIÓN DE LA VACUNACIÓN PARA PREVENCIÓN DE SARS COV-2 EN EL MUNDO.

**Dr. Fernando Bazzino.**

**Dra. Teresa de los Angeles**



Comisión Honoraria para la  
Lucha Antituberculosa y  
Enfermedades Prevalentes



CAMPAÑA DE  
VACUNACIÓN  
COVID-19

JOHNS HOPKINS  
UNIVERSITY & MEDICINE

CORONAVIRUS  
RESOURCE CENTER

Home **Tracking** Testing Tracing Vaccines By Region Events & News About

Tracking Home Critical Trends **Global Map** U.S. Map Data in Motion



COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins U...



Global Cases

**112.072.132**

Cases by  
Country/Region/Sovereignty

**28.255.207** US

**11.016.434** India

**10.257.875** Brazil

**4.146.734** United  
Kingdom

**4.142.126** Russia

**3.689.418** France

**3.161.432** Spain

**2.832.162** Italy

**2.655.633** Turkey

**2.405.263** Germany

**2.233.589** Colombia



Cumulative Cases

Active Cases

Inc. Captura de Pantalla

ality Ratio

Testing Rate

Global Deaths

**2.483.413**

502.449 deaths  
US

248.529 deaths  
Brazil

180.536 deaths  
Mexico

156.463 deaths  
India

121.536 deaths  
United Kingdom

96.348 deaths

Global Deaths

US State Level  
Deaths, Recovered

49.778 deaths,  
recovered  
California US


47.034 deaths,  
recovered  
New York US

42.519  
deaths, **2.331.940**  
recovered  
Texas US

30.213 deaths,  
recovered

US Deaths, ...





Comisión Honoraria para la Lucha Antituberculosa y Enfermedades Prevalentes



CAMPAÑA DE VACUNACIÓN COVID-19



World Health Organization



R&DBlueprint

Powering research to prevent epidemics

## COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide

martes, 23 de Febrero de 2021

**DISCLAIMER:** These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.


### Summary Information on Vaccine Products in Clinical Development

1. - Number of vaccines in clinical development

73

2. - Number of vaccines in pre-clinical development

182





3. - Candidates in clinical phase

Filter:  Select phase of development (default is all)

Platform	Candidate vaccines (no. and %)
PS	Protein subunit 24 33%
VVnr	Viral Vector (non-replicating) 11 15%
DNA	DNA 11 15%
IV	Inactivated Virus 10 14%
RNA	RNA 8 11%
VVr	Viral Vector (replicating) 3 4%
VLP	Virus Like Particle 2 3%
VVr + APC	VVr + Antigen Presenting Cell 2 3%
LAV	Live Attenuated Virus 1 1%
VVnr + APC	VVnr + Antigen Presenting Cell 1 1%

73





Comisión Honoraria para la Lucha Antituberculosa y Enfermedades Prevalentes



CAMPAÑA DE VACUNACIÓN COVID-19



World Health Organization



R&DBlueprint

Powering research to prevent epidemics

## COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide

martes, 23 de Febrero de 2021

**DISCLAIMER:** These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.


### Summary Information on Vaccine Products in Clinical Development

1. - Number of vaccines in clinical development

73

2. - Number of vaccines in pre-clinical development

182





### 3. - Candidates in clinical phase

Filter Phase 3 Select phase of development (default is all)

Platform	Candidate vaccines (no. and %)
PS	Protein subunit 2 13%
VVnr	Viral Vector (non-replicating) 4 25%
DNA	DNA 1 6%
IV	Inactivated Virus 6 38%
RNA	RNA 3 19%
VVr	Viral Vector (replicating) 0 0%
VLP	Virus Like Particle 0 0%
VVr + APC	VVr + Antigen Presenting Cell 0 0%
LAV	Live Attenuated Virus 0 0%
VVnr + APC	VVnr + Antigen Presenting Cell 0 0%

16





Comisión Honoraria para la Lucha Antituberculosa y Enfermedades Prevalentes




CAMPAÑA DE VACUNACIÓN COVID-19




# El paradigma: ¿Cuánto tarda en desarrollarse una nueva vacuna?


## Proceso convencional



## En el contexto de la pandemia (proceso acelerado)



Fuente: 1) Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516-527. 2) <https://gordondougan.blog/2020/04/09/how-to-make-a-new-covid-19-vaccine-starting-from-scratch>  
Editado y adaptado por: Dr. S. Tapia, Prof. J Medina (Cátedra de Enf. Infecc). UDELAR.




Comisión Honoraria para la Lucha Antituberculosa y Enfermedades Prevalentes



CAMPAÑA DE VACUNACIÓN COVID-19

## ¿Cuáles son las vacunas contra el coronavirus más utilizadas?

Número de países que administran las siguientes vacunas contra la COVID-19\*




\* Datos del 16 de febrero de 2021.

Fuente: Our World in Data vía The New York Times

## ¿Cuál vacuna es la más utilizada?


Número de países y territorios utilizando cada vacuna



Nota: solo incluye lugares donde se dispone de datos sobre las dosis administradas.

Fuente: Our World in Data, actualizado el 10 de febrero a las 11:00 GMT.





Comisión Honoraria para la Lucha Antituberculosa y Enfermedades Prevalentes



CAMPAÑA DE VACUNACIÓN COVID-19



## Number of people fully vaccinated against COVID-19, Feb 22, 2021

Total number of people who received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.

Our World in Data


### Vacuna COVID-19: ¿qué países se asegurarán su adquisición?

Número de dosis de vacunas contra la COVID-19 per cápita solicitadas por país/región\*




\* Datos del 20 de noviembre de 2020. Países y regiones seleccionados.

Fuentes: Duke Global Health Innovation Center, ONU DAES, Eurostat, cálculos de Statista



Source: Official data collated by Our World in Data – Last updated 23 February, 10:30 (London time) [OurWorldInData.org/coronavirus](https://OurWorldInData.org/coronavirus) • CC BY




Comisión Honoraria para la  
Lucha Antituberculosa y  
Enfermedades Prevalentes



CAMPAÑA DE  
VACUNACIÓN  
COVID-19

## Proyecciones de la cobertura de vacunación contra la covid-19


■ Finales de 2021   ■ Mediados de 2022   ■ Finales de 2022  
■ Comienzos de 2023



Fuente: Unidad de Inteligencia de The Economist, 27 de enero de 2021

BBC





Comisión Honoraria para la  
**Lucha Antituberculosa y  
Enfermedades Prevalentes**



**CAMPAÑA DE  
VACUNACIÓN  
COVID-19**

Organización de la campaña.

Capacitación.

Monitoreo y verificación  
de coberturas.

Sistema de información.  
Comunicación Social.

Seguridad de vacunas. ESAVI.

Cadena de frío y  
almacena-miento.

Supervisión.

